Herpes virus infections

Clinical information

The family of herpesviruses encompasses more than 100 different virus types, eight of which can cause infections in humans. These so-called human herpesviruses encompass herpes simplex virus of type 1 and 2 (HSV-1 and -2), varicella zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), human herpesviruses 6 and 7 (HHV-6 and -7) as well as human herpesvirus 8 (HHV-8), which is associated with Kaposi sarcoma. Despite great structural similarities of the different pathogens, herpesvirus infection can cause very different diseases, e.g. cold sores or genital herpes, chickenpox, shingles, kissing disease or different cancers. During pregnancy, especially primary infection with particular herpesviruses may lead to severe damage or even loss of the child. There is currently only a vaccine against VZV. After primary infection, which often proceeds asymptomatically, herpesviruses persist life-long in the body in a latent state and may become reactivated at a later time point, e.g. due to a weakened immune system, and (again) cause symptoms.

Diagnostics

Laboratory diagnostics of herpesviruses is based on direct or indirect detection methods. Direct methods, which are especially relevant for diagnostics of acute infections or in immunosuppressed persons include, e.g. virus culture or PCR-based tests, in which viral nucleic acids are detected. Blister liquid, skin or mucosal smears, blood, CSF or broncoalveolar lavage fluid is used as sample material. If the herpesvirus specific antibody is detected in patient serum, plasma or CSF, this is considered as indirect pathogen detection. The antibody detection not only allows conclusions to be drawn on which virus is present in the patient, but can also contribute to the differentiation of primary and recurrent infections. EUROIMMUN offers a broad spectrum of products for the detection of herpesvirus infections, including both antibody detection and direct detection methods.

Selected Products

Method
Parameter
Substrate
Species/ Antigen
PCR
EURORealTime HSV-1/2
IIFT
antibodies against Herpes simplex virus 1 (HSV-1)
IgG positive control
IIFT
antibodies against Herpes simplex virus 1 (HSV-1)
IgM positive control
IIFT
Herpes simplex virus 1
(HSV-1)
infected cells
EU 38
IIFT
HSV-1/HSV-2
negative control
WESTERNBLOT
antibodies against Herpes simplex virus (HSV)
IgG positive control
IIFT
BIOCHIP Mosaic
HSV-1/HSV-2
2 BIOCHIPs per field:
infected cells

EU 38
ELISA
CSQ pair of controls
anti-HSV-1/2 Pool (IgG)
ELISA
Herpes simplex virus
(HSV-1/2 Pool)
antigen-coated
microplate wells
native antigens
from HSV-1 and HSV-2
ELISA
Herpes simplex virus
(HSV-1/2 Pool)
antigen-coated
microplate wells
native antigens
from HSV-1 and HSV-2
ELISA
Herpes simplex virus
(HSV-1/2 Pool)
antibody determination in CSF
antigen-coated
microplate wells
native antigens
from HSV-1 and HSV-2
ELISA
Herpes simplex virus
(HSV-1/2 Pool)
incl. IgG/RF absorbent
antigen-coated
microplate wells
native antigens
from HSV-1 and HSV-2
WESTERNBLOT
EUROLINE-WB
Herpes simplex virus 1 (HSV-1)
plus HSV-2 type-specific
glycoprotein G2
Westernblot
whole antigen, SDS extract of HSV-1
plus purified gG2
ELISA
Herpes simplex virus 1 (HSV-1)
incl. IgG/RF absorbent
antigen-coated
microplate wells
native
glycoprotein C1
ELISA
Herpes simplex virus 1
(HSV-1)
antigen-coated
microplate wells
recombinant
glycoprotein C1
IIFT
antibodies against Herpes simplex virus 2 (HSV-2)
IgG positive control
IIFT
antibodies against Herpes simplex virus 2 (HSV-2)
IgM positive control
IIFT
Herpes simplex virus 2
(HSV-2)
infected cells
EU 38
ELISA
Herpes simplex virus 2 (HSV-2)
incl. IgG/RF absorbent
antigen-coated
microplate wells
recombinant
glycoprotein G2
ELISA
Herpes simplex virus 2
(HSV-2)
antigen-coated
microplate wells
recombinant
glycoprotein G2
IIFT
antibodies against HHV-6
IgG positive control
IIFT
antibodies against HHV-6
IgM positive control
IIFT
HHV-6
infected cells
EU 30
IIFT
HHV-6 EUROPattern
infected cells
EU 30
IIFT
HHV-6
negative control
IIFT
antibodies against Cytomegalovirus (CMV)
IgA positive control
IIFT
antibodies against Cytomegalovirus (CMV)
IgG positive control
IIFT
antibodies against Cytomegalovirus (CMV)
IgM positive control
IIFT
Cytomegalovirus (CMV)
negative control
IIFT
Cytomegalovirus
(CMV)
infected cells
EU 168
IIFT
high-avid antibodies against Cytomegalovirus (CMV)
IgG positive control
IIFT
low-avid antibodies against Cytomegalovirus (CMV)
IgG positive control
ELISA
Cytomegalovirus (CMV)
incl. IgG/RF absorbent
antigen-coated
microplate wells
native antigens
from CMV
ELISA
Cytomegalovirus
(CMV)
antigen-coated
microplate wells
native antigens
from CMV
ELISA
Cytomegalovirus (CMV)
avidity determination
antigen-coated
microplate wells
native antigens
from CMV
ELISA
Cytomegalovirus (CMV) p52
incl. IgG/RF absorbent
antigen-coated
microplate wells
native antigens
from CMV
ELISA
Cytomegalovirus
(CMV) gB
antigen-coated
microplate wells
recombinant
glycoprotein B antigen from CMV
ELISA
CSQ pair of controls
anti-Cytomegalovirus (IgG)
ELISA
Cytomegalovirus (CMV)
antibody determination in CSF
antigen-coated
microplate wells
native antigens
from CMV
IIFT
antibodies against Varicella zoster virus (VZV)
IgA positive control
IIFT
antibodies against Varicella zoster virus (VZV)
IgG positive control
IIFT
antibodies against Varicella zoster virus (VZV)
IgM positive control
IIFT
high-avid antibodies against Varicella zoster virus (VZV)
IgG positive control
IIFT
low-avid antibodies against Varicella zoster virus (VZV)
IgG positive control
IIFT
Varicella zoster virus (VZV)
negative control
IIFT
Varicella zoster virus
(VZV)
infected cells
EU 168
ELISA
Varicella zoster virus (VZV)
incl. IgG/RF absorbent
antigen-coated
microplate wells
native antigens
from VZV
ELISA
Varicella zoster virus
(VZV)
antigen-coated
microplate wells
native antigens
from VZV
ELISA
Varicella zoster virus
(VZV)
antigen-coated
microplate wells
native antigens
from VZV
ELISA
Varicella zoster virus (VZV)
avidity determination
antigen-coated
microplate wells
native antigens
from VZV
ELISA
Varicella zoster virus (VZV) glycoprotein
incl. IgG/RF absorbent
antigen-coated
microplate wells
native glycoproteins
from VZV
ELISA
CSQ pair of controls
anti-VZV (IgG)
ELISA
Varicella zoster virus (VZV)
antibody determination in CSF
antigen-coated
microplate wells
native antigens
from VZV
ELISA
Varicella zoster virus (VZV)
antibody determination in CSF
antigen-coated
microplate wells
native antigens
from VZV
WESTERNBLOT
antibodies against Epstein-Barr virus (EBV)
IgG positive control
WESTERNBLOT
antibodies against Epstein-Barr virus (EBV)
IgM positive control
WESTERNBLOT
Epstein-Barr virus
(EBV)
Westernblot
whole antigen,
SDS extract
EUROLINE
positive control serum: IgG, human, 50x concentrated
for EBV-Profil 2 G
EUROLINE
positive control serum: IgM, human, 50x concentrated
for EBV-Profil 2 M
EUROLINE
EBV Profile 2
(VCA gp125, VCA p19,
EBNA-1, p22, EA-D separately)
EUROLINE
IIFT
antibodies against Epstein-Barr virus capsid antigen (EBV-CA)
IgA positive control
IIFT
antibodies against Epstein-Barr virus capsid antigen (EBV-CA)
IgG positive control
IIFT
antibodies against Epstein-Barr virus capsid antigen (EBV-CA)
IgM positive control
IIFT
Epstein-Barr virus (EBV)
negative control
IIFT
Epstein-Barr
virus capsid antigen
(EBV-CA)
expressing cells
P3HR1
IIFT
Epstein-Barr
virus capsid antigen
(EBV-CA) EUROPattern
expressing cells
P3HR1
IIFT
high-avid antibodies against Epstein-Barr virus capsid antigen (EBV-CA)
IgG positive control
IIFT
low-avid antibodies against Epstein-Barr virus (EBV-CA)
IgG positive control
ELISA
Epstein-Barr virus capsid antigen
(EBV-CA)
antigen-coated
microplate wells
native, mixture of several
viral capsid antigens
ELISA
Epstein-Barr virus capsid antigen
(EBV-CA)
antigen-coated
microplate wells
native, mixture of several
viral capsid antigens
ELISA
Epstein-Barr virus capsid antigen
(EBV-CA) incl. IgG/RF absorbent
antigen-coated
microplate wells
native gp125
of EBV
ChLIA
control set
Epstein-Barr virus capsid antigen (EBV-CA)
ChLIA
Epstein-Barr virus capsid antigen
(EBV-CA)
recombinant
p18, gp125
ChLIA
Epstein-Barr virus capsid antigen
(EBV-CA)
recombinant
p18, p23, gp125
ELISA
Epstein-Barr virus capsid antigen
(EBV-CA) avidity determination
antigen-coated
microplate wells
native, mixture of several
viral capsid antigens
IIFT
EBV capsid antigen (EBV-CA)
EBV early antigen (EBV-EA)
expressing cells
(2 BIOCHIPs per field)
P3HR1
EU 33
IIFT
EUROPLUS
EBV capsid antigen (EBV-CA)
gp125 antigen
p19 antigen
4 BIOCHIPs per field:
expressing cells
gp125 BIOCHIPs
p19 BIOCHIPs
antigen-free BIOCHIP

P3HR1
native
recombinant
EU 120
ELISA
CSQ pair of controls
anti-EBV-CA (IgG)
ELISA
Epstein-Barr virus capsid antigen
(EBV-CA) antibody determination in CSF
antigen-coated
microplate wells
native, mixture of several
viral capsid antigens
IIFT
antibodies against Epstein-Barr virus nuclear antigen (EBNA)
complement-binding, positive control
IIFT
Epstein-Barr virus nuclear antigen
(EBNA) EUROPattern
expressing cells
Raji
IIFT
Epstein-Barr virus
nuclear antigen (EBNA,
complement-fixing antibodies)
expressing cells
Raji
ELISA
Epstein-Barr virus nuclear antigen
(EBNA-1)
antigen-coated
microplate wells
recombinant
EBNA-1 from EBV
ChLIA
control set
Epstein-Barr virus nuclear antigen 1 (EBNA-1)
ChLIA
Epstein-Barr virus nuclear antigen 1
(EBNA-1)
recombinant
EBNA-1
IIFT
antibodies against Epstein-Barr virus early antigen (EBV-EA)
IgA positive control
IIFT
antibodies against Epstein-Barr virus early antigen (EBV-EA)
IgG positive control
IIFT
Epstein-Barr
virus early antigen
(EBV-EA)
expressing cells
EU 33
IIFT
Epstein-Barr
virus early antigen
(EBV-EA) EUROPattern
expressing cells
EU 33
ELISA
Epstein-Barr virus early antigen
(EBV-EA)
antigen-coated
microplate wells
recombinant early antigen D
from EBV
ELISA
Epstein-Barr virus early antigen
(EBV-EA)
antigen-coated
microplate wells
recombinant early antigen D
from EBV
ELISA
Epstein-Barr virus early antigen
(EBV-EA) incl. IgG/RF absorbent
antigen-coated
microplate wells
recombinant early antigen D
from EBV
IIFT
BIOCHIP
Sequence EBV
fields A and B: EBV-CA (IgG)
field C: EBV-CA (IgM)
field D: EBV-EA
field E: EBNA


expressing cells
expressing cells
expressing cells
expressing cells


P3HR1
P3HR1
EU 33
Raji
IIFT
EUROPLUS
BIOCHIP Sequence EBV
field A: EBV-CA (IgG), gp125 ag, p19 ag

field B: EBV-CA (IgG)
field C: EBV-CA (IgM), gp125 ag, p19 ag

field D: EBV-EA
field E: EBNA


expr. cells, gp125/p19/
ag-free BIOCHIP
expressing cells
expressing cells
expr. cells, gp125/p19/
ag-free BIOCHIP
expressing cells


P3HR1, native/rec.
EU 120
P3HR1
P3HR1, native/rec.
EU 120
EU 33
Raji
Back to top
Contact person on site
Please click on a country or enter yours
North America
South & Central America
Europe
Asia
Oceania
Middle East & Africa